This Biotech Stock Is Jumping 25% After Getting an FDA Boost - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# This Biotech Stock Is Jumping 25% After Getting an FDA BoostBy [Adam Clark]ShareResize---ReprintsIn this article[NVCR]Novocure's Op ...

NovoCure Ltd (NASDAQ:NVCR) shares are trending on Thursday.Shares of the oncology company surged 29.52% to $13.60 in after-hours trading on Wednesday after the Food and Drug Administration approved Optune Pax for the treatment of locally advanced pancreatic cancer.First Approval In Three DecadesThe approval marks the first new treatment for locally advanced pancreatic cancer in nearly 30 years, according to the company’s announcement. Optune Pax, which is a portable therapeutic device that delivers Tumor Tr ...

The Swiss biopharmaceutical company's shares surged in after-hours trading after it said the FDA approved its Optune Pax product. ...